



Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.: OC01000KQ	APPLICATION NO.: 09/904,263		
				APPLICANT: Mary Ellen Rybak, et al.			
				FILING DATE: 07/12/2001	GROUP: 1642		
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
ARH	AA	Bruno, René, et al., "Population Pharmacokinetics/Pharmacodynamics of Docetaxel in Phase II Studies in Patients with Cancer," <i>Journal of Clinical Oncology</i> 16(1):187-96 (1998)					
ARH	AB	Calvert, A.H., et al., "Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function," <i>Journal of Clinical Oncology</i> 7(11):1748-56 (1989)					
ARH	AC	Eisenhauer, Elizabeth A., et al., "The Taxoids, Comparative Clinical Pharmacology and Therapeutic Potential," <i>Drugs</i> 55(1):5-30 (1998)					
ARH	AD	Eksborg, Steffan, et al., "Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite-a comparison of bolus versus 2 h infusion during a 3 day course," <i>Anti-Cancer Drugs</i> 8:42-7 (1997)					
ARH	AE	Forastiere, Arlene A., et al., "Pharmacokinetic and Toxicity Evaluation of Five-Day Continuous Infusion versus Intermittent Bolus cis-Diamminedichloroplatinum(II) in Head and Neck Cancer Patients," <i>Cancer Research</i> 48:3869-3874 (1988)					
ARH	AF	Gandhi, Varsha, et al., "Compound GW506U78 in Refractory Hematologic Malignancies: Relationship Between Cellular Pharmacokinetics and Clinical Response," <i>Journal of Clinical Oncology</i> 16(11):3607-15 (1998)					
ARH	AG	Rodman, John H., et al., "Clinical Pharmacodynamics of Continuous Infusion Teniposide: Systemic Exposure as a Determinant of Response in a Phase I Trial," <i>Journal of Clinical Oncology</i> 5(7):1007-1014 (1987)					
ARH	AH	Shalinsky, David R., et al., "Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations," <i>Investigational New Drugs</i> 16:303-13 (1999)					
ARH	AI	Takitani, Kimitaka, et al., "4-Oxo Retinoic Acid for Refractory Acute Promyelocytic Leukemia in Children with All-Trans Retinoic Acid Therapy," <i>J. Nutr. Sci. Vitaminol.</i> 41:493-98 (1995)					
EXAMINER <i>Anne L. McLean</i>			DATE CONSIDERED 6/25/2004				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							